medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2014, Number 1

<< Back Next >>

Ann Hepatol 2014; 13 (1)

Statin use is not associated with liver related mortality

Younoszai Z, Zheng L, Stepanova M, Erario M, Cable R, Younossi ZM

Language: English
References: 22
Page: 84-90
PDF size: 88.75 Kb.


ABSTRACT

Background and Aim. Statins are commonly used medications for the treatment of dyslipidemia. Although there are reported cases of hepatotoxicity related to statins, very few are associated with severe course and liver failure. Material and methods. We used the Third National Health and Nutrition Examination Survey (NHANES III)-mortality linked files to assess the association between statin use and liver-related mortality. Patients with established causes of liver disease (HCV RNA-positive, HBs-Ag-positive, NAFLD by hepatic ultrasound, iron overload and excessive alcohol use of › 20 g of alcohol per day with elevated liver enzymes) were excluded. Results. Of all adult NHANES III participants enrolled in 1988-1994 (n = 20,050), 9,207 individuals had sufficient demographic, clinical and medical information making them eligible for this study (age 41.26 ± 0.38, 46.76% male, 76.67% Caucasian, BMI 26.39 ± 0.38, 16.99% had diabetes or insulin resistance, 16.97% had hypertension, 65.28% had dyslipdemia). Of the entire study cohort, 90 (1.25%) participants reported using statins at the time of the interview. Median mortality follow-up for the study cohort was 175.54 months. During this period, 1,330 individuals (11.25%) died with 26 (0.17%) being liver-related deaths. For the cohort using statins, there were 37 deaths (40.15%) after a median follow-up of 143.35 months. In fact, the top cause of death for statin users was cardiac related (16 cases, 33.62%). However, after adjusting for major demographic, clinical and metabolic confounders, statin use was not associated with cardiovascular deaths in males (Hazard Ratio, 0.79, 95% Confidence Interval, 0.30-2.13), but was associated with higher risk of cardiovascular deaths in females (odds ratio, 2.32, 95% confidence interval, 1.58-3.40). Furthermore, the rate of liver-related mortality was significantly lower (p = 0.0035) among statin users compared to non-statin users. Conclusions. After a decade of follow up, there was no association between statin use and liver-related mortality.


REFERENCES

  1. Coronary Heart Disease. A.D.A.M. Medical Encyclopedia. http://www. ncbi. nlm. nih. gov/pubmedhealth/PMH0004449/.

  2. Sikka P, Saxena KK, Kapoor S. Statin Hepatotoxicity: Is it a Real Concern? Heart Views 2011; 12(3): 104-6.

  3. Ahmed MH, Al-Atta A, Hamad MA. The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges. Expert Opin Pharmacother 2012.

  4. Liakopoulos OJ, Kuhn EW, Slottosch I, Wassmer G, Wahlers T. Preoperative statin therapy for patients undergoing cardiac surgery. Cochrane Database Syst Rev 2012; 4: CD008493.

  5. Ko DT, Wijeysundera HC, Yun L, Austin PC, Cantor WJ, Tu JV. Effectiveness of preprocedural statin therapy on clinical outcomes for patients with stable coronary artery disease after percutaneous coronary interventions. Circ Cardiovasc Qual Outcomes 2011; 4(4): 459-66.

  6. Warita S, Kawasaki M, Tanaka R, Ono K, Kojima T, Hirose T, Iwama M, et al. Effects of pitavastatin on cardiac structure and function and on prevention of atrial fibrillation in elderly hypertensive patients. Circ J 2012 Aug 8. [Epub ahead of print]

  7. Tian J, Gu X, Sun Y, Ban X, Xiao Y, Hu S, Yu B. Effect of statin therapy on the progression of coronary atherosclerosis. BMC Cardiovasc Disord 2012; 12(1): 70. [Epub ahead of print]

  8. Ali OF, Growcott EJ, Butrous GS, Wharton J. Pleiotropic effects of statins in distal human pulmonary artery smooth muscle cells. Respir Res 2011; 12: 137.

  9. Rzouq FS, Volk ML, Hatoum HH, Talluri SK, Mummadi RR, Sood GK. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. Am J Med Sci 2010; 340(2): 89-93.

  10. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142(7): 1592-609.

  11. Younossi ZM, Venkatesan C. A 2012 clinical update for internists in adult nonalcoholic fatty liver disease. Panminerva Med 2012; 54(1): 29-37.

  12. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol 2012; 6(3): 208-15.

  13. FDA Expands Advice on Statin Risks. U.S. Food and Drug Administration. http://www.fda.gov/ForConsumers/ConsumerUpdates/ ucm293330.htm

  14. Tandra S, Vuppalanchi R. Use of statins in patients with liver disease. Curr Treat Options Cardiovasc Med 2009; 11(4): 272-8.

  15. Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis 2009; 29(4): 412-22.

  16. U.S. department of health and human services (DHHS). National center for health statistics. third national health and nutrition examination survey, 1988-1994, NHANES III household adult data file. public use data file documentation number 77560. Hyattsville, MD. Centers for Disease Control and Prevention; 1996.

  17. Third national health and nutrition examination survey (NHANES III) linked mortality file public-use file layout. http://www.cdc.gov/nchs/data/datalinkage/nh3_file_layout_public_2010.pdf

  18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28(7): 412-19.

  19. Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 2010; 59(10): 1410-15.

  20. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing. J Hepatol 2012; 56: 374-80.

  21. Teschke R. Hepatotoxicity associated with statins. Ann Hepatol 2012; 11; 418-20.

  22. Teschke R, Frenzel C, Wolff A, Eickhoff A. Rare statin hepatotoxicity: Convincing evidence based on breakthrough case study. J Hepatol 2012; 57: 699-700.




2020     |     www.medigraphic.com